Oriola (ORIOLA)
Helsinki Exchange · Finland · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 0.753 |
|---|---|
| 52-week range | 0.726 – 1.260 |
| Return, 1 month / 3 months | −17.4% / −16.3% |
| Return, 1 year / 3 years | −30.1% / −3.2% |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 22.2% |
| Worst drawdown (1 year) | -39.2% |
| Average daily value traded | 0.14M EUR |
| Dividend yield | 4.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Oriola is a Finnish healthcare and pharmaceutical company based in Finland. It distributes medicines and health products to pharmacies, hospitals and other healthcare providers, and it runs pharmacy chains in Finland and Sweden. The company also offers services such as dose dispensing and pharmaceutical consulting to support patient care. Its customers include pharmacies, healthcare organisations and consumers who rely on its distribution and pharmacy operations across the Nordic region.
The shares are listed on the Helsinki Exchange in Finland under the code ORIOLA, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Oriola (ORIOLA) trades on the Helsinki Exchange in Finland. It last closed at EUR 0.753 on 23 October 2026.
Its price-based Market X-Ray is 38 out of 100 (a weak price profile), ranking 141 of 190 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 30.1% and over the last three months it fell 16.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Helsinki Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 18 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -20.3% | ||
| From 52-week high | -40.0% | ||
| Momentum | 20 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -16.3% | ||
| 6-month return | -19.9% | ||
| 12-month return, skipping the last month | -15.4% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 22.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.2% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.14M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 57 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.0% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +0.8% |
|---|---|
| 1 month | −17.4% |
| 3 months | −16.3% |
| 6 months | −19.9% |
| 1 year | −30.1% |
| 3 years | −3.2% |
| 5 years | −46.6% |
Signals
| 50-day / 200-day average | 0.852 / 0.944 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.019 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 26 Mar 2026 | EUR 0.0300 |
| 3 Apr 2025 | EUR 0.0700 |
| 20 Mar 2024 | EUR 0.0700 |
| 22 Mar 2023 | EUR 0.0600 |
| 16 Mar 2022 | EUR 0.0400 |
| 17 Mar 2021 | EUR 0.0300 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Helsinki Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.